Eric S. Furfine

5.3k total citations · 1 hit paper
73 papers, 4.3k citations indexed

About

Eric S. Furfine is a scholar working on Infectious Diseases, Molecular Biology and Virology. According to data from OpenAlex, Eric S. Furfine has authored 73 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Infectious Diseases, 25 papers in Molecular Biology and 24 papers in Virology. Recurrent topics in Eric S. Furfine's work include HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (24 papers) and Nitric Oxide and Endothelin Effects (10 papers). Eric S. Furfine is often cited by papers focused on HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (24 papers) and Nitric Oxide and Endothelin Effects (10 papers). Eric S. Furfine collaborates with scholars based in United States, United Kingdom and India. Eric S. Furfine's co-authors include Edward P. Garvey, Jeffrey A. Oplinger, John E. Reardon, Richard G. Knowles, B.J.R. Whittle, Ferenc László, Lois L. Wright, Andrew Spaltenstein, Barbara Maschera and Edward D. Blair and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Eric S. Furfine

73 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo

1997 727 citations Edward P. Garvey, Jeffrey A. Oplinger et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric S. Furfine United States	33	1.4k	1.2k	1.2k	1.1k	595	73	4.3k
Thomas D. Meek United States	33	2.9k 2.0×	1.4k 1.2×	1.1k 0.9×	1.1k 1.0×	854 1.4×	70	5.3k
Edward P. Garvey United States	39	1.5k 1.1×	1.9k 1.6×	1.3k 1.1×	655 0.6×	727 1.2×	82	5.1k
Karl Y. Hostetler United States	50	3.3k 2.3×	1.4k 1.1×	855 0.7×	1.2k 1.1×	345 0.6×	183	7.0k
André B. P. Kuilenburg Netherlands	47	6.3k 4.5×	812 0.7×	949 0.8×	367 0.3×	438 0.7×	277	10.1k
Mélanie Ott United States	57	5.3k 3.7×	2.1k 1.7×	1.3k 1.0×	2.7k 2.5×	172 0.3×	137	10.9k
James E. Strickler United States	31	3.4k 2.4×	823 0.7×	256 0.2×	766 0.7×	798 1.3×	47	6.1k
Marçal Pastor‐Anglada Spain	42	1.8k 1.3×	750 0.6×	342 0.3×	200 0.2×	87 0.1×	184	5.6k
Kim M. Gernert United States	24	2.0k 1.4×	356 0.3×	731 0.6×	134 0.1×	273 0.5×	40	4.0k
Andreas Billich Austria	42	4.6k 3.3×	531 0.4×	576 0.5×	574 0.5×	716 1.2×	131	6.8k
Sara Colombo Italy	32	1.8k 1.2×	1.1k 0.9×	286 0.2×	773 0.7×	46 0.1×	75	4.0k

Countries citing papers authored by Eric S. Furfine

Since Specialization

Citations

This map shows the geographic impact of Eric S. Furfine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Furfine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Furfine more than expected).

Fields of papers citing papers by Eric S. Furfine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric S. Furfine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Furfine. The network helps show where Eric S. Furfine may publish in the future.

Co-authorship network of co-authors of Eric S. Furfine

This figure shows the co-authorship network connecting the top 25 collaborators of Eric S. Furfine. A scholar is included among the top collaborators of Eric S. Furfine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric S. Furfine. Eric S. Furfine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Furfine, Eric S., et al.. (2019). Pegylated CB2782: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD. Investigative Ophthalmology & Visual Science. 60(9). 374–374. 2 indexed citations

Furfine, Eric S., Martin Stanton, Nassim Usman, et al.. (2018). Discovery and Planned Optimization of a Complement Factor C3-Inactivating Alterase, CB-2782. Investigative Ophthalmology & Visual Science. 59(9). 60–60. 1 indexed citations

Goldstein, Michael H., Joseph R. Martel, Kenneth Sall, et al.. (2016). Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye & Contact Lens Science & Clinical Practice. 43(5). 287–296. 19 indexed citations

Schmidt, Michael, et al.. (2015). Optimized intravitreal IL-6 antagonist for the treatment of diabetic macular edema. Investigative Ophthalmology & Visual Science. 56(7). 3488–3488. 2 indexed citations

Tubridy, Karen L., et al.. (2015). Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation. Investigative Ophthalmology & Visual Science. 56(7). 4488–4488. 1 indexed citations

Goldstein, Michael H., Karen L. Tubridy, Eric S. Furfine, et al.. (2015). A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis. Eye & Contact Lens Science & Clinical Practice. 41(3). 145–155. 18 indexed citations

Schmidt, Michael, et al.. (2014). Optimized IL-6 Blockade for the Treatment of Diabetic Macular Edema. Investigative Ophthalmology & Visual Science. 55(13). 1062–1062. 6 indexed citations

Furfine, Eric S., et al.. (2013). Preclinical Development of EBI-005: a Potent Interleukin-1 (IL-1) Receptor-1 (R1) Blocker for Topical Ocular Administration was Safe in GLP Toxicology Studies and Active in a Mouse Model of Dry Eye Disease (DED). Investigative Ophthalmology & Visual Science. 54(15). 4320–4320. 2 indexed citations

Schmidt, Michael M., Sharon A. Townson, Amy Andreucci, et al.. (2013). Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface. Structure. 21(11). 1966–1978. 92 indexed citations

10.

Tolcher, Anthony W., Christopher J. Sweeney, K. Papadopoulos, et al.. (2011). Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. Clinical Cancer Research. 17(2). 363–371. 67 indexed citations

11.

Furfine, Eric S., et al.. (2006). Pharmacokinetics and Ocular Tissue Penetration of VEGF Trap After Intravitreal Injections in Rabbits. Investigative Ophthalmology & Visual Science. 47(13). 1430–1430. 15 indexed citations

12.

Wiegand, Stanley J., T. Michael Nork, Paul E. Miller, et al.. (2005). VEGF Trap Both Prevents Experimental Choroidal Neovascularization and Causes Regression of Established Lesions in Non–Human Primates. Investigative Ophthalmology & Visual Science. 46(13). 1411–1411. 4 indexed citations

13.

Miller, John F., Eric S. Furfine, Richard Hazen, et al.. (2005). Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorganic & Medicinal Chemistry Letters. 15(15). 3496–3500. 15 indexed citations

14.

Catalano, John G., David N. Deaton, Eric S. Furfine, et al.. (2003). Exploration of the P1 SAR of aldehyde cathepsin K inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(1). 275–278. 32 indexed citations

15.

Kazmierski, Wieslaw M., Eric S. Furfine, Andrew Spaltenstein, & Lois L. Wright. (2002). Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease. Bioorganic & Medicinal Chemistry Letters. 12(23). 3431–3433. 39 indexed citations

16.

Garvey, Edward P., Jeffrey A. Oplinger, Eric S. Furfine, et al.. (1997). 1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo. Journal of Biological Chemistry. 272(8). 4959–4963. 727 indexed citations breakdown →

17.

Garvey, Edward P., Eric S. Furfine, & Paula Sherman. (1996). Purification and inhibitor screening of human nitric oxide synthase isozymes. Methods in enzymology on CD-ROM/Methods in enzymology. 268. 339–349. 10 indexed citations

18.

Furfine, Eric S., et al.. (1992). Two-step binding mechanism for HIV protease inhibitors. Biochemistry. 31(34). 7886–7891. 54 indexed citations

19.

Furfine, Eric S. & John E. Reardon. (1991). Human immunodeficiency virus reverse transcriptase ribonuclease H: specificity of tRNALys3-primer excision. Biochemistry. 30(29). 7041–7046. 62 indexed citations

20.

Furfine, Eric S., Theodore C. White, Alice L. Wang, & Ching C. Wang. (1989). A single-straded RNA copy of theGiardia lambliavirus double-stranded RNA genome is present in the infectedGiardia lamblia. Nucleic Acids Research. 17(18). 7453–7467. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact